Search
Atara Biotherapeutics Inc
ATRAAdd to Watchlist
11.650USD
+0.280+2.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
84.00MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Atara Biotherapeutics Inc is 7.50, ranking 286 out of 387 in the Biotechnology & Medical Research industry. The average price target is 17.00, with a high of 18.00 and a low of 16.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
13.667
Target Price
+20.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Atara Biotherapeutics Inc
ATRA
4
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Atara Biotherapeutics Inc's expected revenue for the next quarter?
Atara Biotherapeutics Inc's expected revenue is 366.67K.
What is Atara Biotherapeutics Inc's price target?
Analysts forecast that Atara Biotherapeutics Inc's price target is USD 17.00, with the highest forecast at USD 18.00 and the lowest forecast at USD 16.00.
How have Atara Biotherapeutics IncATRA's recent earnings per share performed?
The market expectation was USD -0.29, while Atara Biotherapeutics IncATRA's earnings per share (EPS) for the previous quarter was USD -0.25. EPS for the next quarter is expected at USD -0.32.
What is the analyst rating for Atara Biotherapeutics Inc?
Based on the ratings of Atara Biotherapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.